Press Releases [2007]
GENEGO INTEGRATES WITH CYTOSCAPE St. Joseph, MI. December 18th, 2007 – GeneGo, Inc., the leading provider of databases,
software and services in systems biology, announced today that its platforms for functional
data analysis, MetaCore and MetaDrug, are now integrated with Cytoscape. MetaCore users
will now be able to use Cytoscape network visualization tools and have access to dozens of its
open source and commercial plug-ins. The integrated solution was presented at the Cytsocape
annual meeting in Amsterdam, November 6-9.
TNO EXTENDS LICENSING AGREEMENT WITH GENEGO AGAIN St. Joseph, MI. December 4th, 2007 – GeneGo, Inc., the leading systems biology tools
company, announced today that TNO, The European Nutrigenomics Organisation (NUGO)
Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their
agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre
(NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.
ELAN PHARMACEUTICALS JOINS GENEGO'S METATOX CONSORTIUM St. Joseph, MI. November 27th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery™ platform with toxicity ontologies, developing “knowledge-based” predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the development of simplified workflows for analyzing and reporting systems toxicology data. These tools, unique to the marketplace, will enable the members to leverage their diverse molecular toxicology data in an integrated “systems’ perspective that has not been available until now. “The MetaTox Consortium is a cost effective vehicle for the members to develop software and expand content in systems toxicology,” said Julie Bryant, Vice President of Business Development for GeneGo. “The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members’ input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model.” “Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment”, said Dr. Richard Brennan, Director of Toxicology at GeneGo, “The Consortium, which includes representatives from industry and from FDA, believes that part of the problem lies in a lack of appropriate data analysis tools to properly integrate the multiple data types generated by data-rich ‘omics technologies, and to convert findings from cell-based and animal models into meaningful human risk-assessments. We will focus on developing novel predictive models, while expanding our knowledge-base of toxicity information, and developing new software for ‘omics data analysis in a systems biology perspective. Alongside GeneGo’s expertise in identifying and mapping differences in human and model-species biology, these tools will facilitate a better assessment of the potential for human toxicity from preclinical tests, increasing the quality of, and confidence in, new compounds going into clinical trials. They will also contribute to understanding the causes of failure for compounds that drop out of trials, or are withdrawn from the market, for safety reasons, allowing these liabilities to be screened out of follow-up molecules.”
UTRECHT UNIVERSITY LICENSES METADRUG™ FROM GENEGO FOR DRUG INNOVATION St. Joseph, MI. November 20th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug™ in their prestige master program for drug innovation. MetaDrug™ is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL’s Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases. “Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug™ is state-of-the-art, but still very accessible to the novice user,” said Dr Ed Moret. “We really like the support and training they have offered to our students.” “GeneGo is very serious about including MetaDrug™ in academic environments especially for teaching,” said Julie Bryant, Vice President of Business Development for GeneGo. “Academia pushes the limits of MetaDrug™ which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way.”
ELAN PHARMACEUTICALS, INC. LICENSES SOFTWARE AND DATABASES FROM GENEGO St. Joseph, MI. October 30th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore™ is designed for functional analysis of biological and chemistry data. Elan will use MetaCore™ in their neurology and autoimmune programs. “We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore™ has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research.”
GENEGO LICENSES METACORE™ DATA ANALYSIS SUITE TO AVEO PHARMACEUTICALS St. Joseph, Michigan, October 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that they have licensed their MetaCore™ Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5™, includes novel GeneGo disease enrichment and functional ontology. MetaCore™ has an in depth knowledge base for human diseases and the unique ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite’s data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore™ a robust OMICs repository platform of choice. MetaCore™ is used in both research and clinical groups in drug development. “We are pleased that AVEO chose the MetaCore™ suite of products to enhance its analytical capabilities,” says Julie Bryant, Vice President of GeneGo. “AVEO’s vision and focus in cancer drug research and development is inspiring and we believe our MetaCore™ suite of data mining tools will be an asset to their efforts.”
ORGANON EXTENDS METACORE™ LICENSE AND ADDS METALINK™ St. Joseph, MI. October 2nd, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore™ license, Organon has also added MetaLink™ so that they can upload their own interaction data and visualize it in the context of MetaCore’s manually curated content. GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow™ which is a “pay as you go” business model. GeneGo also covers human, mouse, rat, dog, worm, chicken, fly, chimpanzee and yeast which is very important for our customers. “GeneGo has demonstrated the capability to develop a good pharma oriented bioinformatics tool in the past years” said Peter Groenen, project manager for pharmacogenetics at Organon. “We have now started to use their software for more advanced projects to support our translational medicine efforts”. “Organon has been a good, loyal GeneGo customer for years and we are pleased they have extended their license,” said Julie Bryant, GeneGo’s VP of Business Development. “We have received good development feedback from Organon over the years and implemented many of their ideas in MetaCore™”.
GENEGO ENTERS MULTI-YEAR AGREEMENT WITH BRISTOL MYERS SQUIBB FOR ACCESS TO GENEGO SOFTWARE SUITE AND DATABASES St. Joseph, MI. September 25th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation. “Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with,” said Julie Bryant, GeneGo’s VP of Business Development. “We plan to continue this collaborative spirit over the next few years.”
GENEGO AND THE CYSTIC FIBROSIS FOUNDATION COLLABORATE TO ADVANCE UNDERSTANDING OF CYSTIC FIBROSIS St. Joseph, MI. September 11th, 2007 — GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo’s proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases. “We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level,” said Robert J. Beall, Ph.D., president and CEO of the Foundation. “Using computational platforms adds to our arsenal of already existing strategies.” The new platform, called MetaMiner™ (CF), will include off-the-shelf GeneGo products such as MetaCore™, MetaDrug™, MetaLink™ and MapEditor™. Platforms such as MetaDrug™ can help to solve various problems including a drug’s mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner™ (CF) will include cystic fibrosisspecific OMICs and small experiments content annotated by GeneGo, disease maps and networks. “We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on,” said Julie Bryant, GeneGo’s vice president of business development. “This collaboration is the first in the series of diseasecentered MetaMiner™ projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project.” The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner™ (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses. Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, including 94 adult programs, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
NHLBI EXTENDS GENEGO LICENSE AGAIN St. Joseph, MI. September 4th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that National Heart Lung and Blood Institute have extended their license again. Hundreds of researchers will have access to MetaCore™ at the NHLBI for analysis of different types of “omics” data such as gene expression, proteomics, metabolomics and SNPs and MPSS. MetaCore™ is known for its comprehensive functional ontologies including cellular and molecular processes, canonical metabolic and signaling pathways, diseases and disease networks and biomakers. The NHLBI Genomic Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. As a central part of its role, the core provides computational and research tools to investigators and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. Genego’s Metacore™ data mining software would provide statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes and DNA sequence variations. It is hoped that the application of this Metacore™ analysis program would help us decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine. “We are pleased to have a strong, long lasting relationship with NIH as they are the best known research organization in biomedicine,” said Julie Bryant, GeneGo’s VP of Business Development. “Over the years, their valuable feedback has helped GeneGo to develop new features and products, and we look forward to expanding relationships with their labs”.
GENEGO ANNOUNCES LICENSING AGREEMENT WITH BIOGEN IDEC St. Joseph, MI. August 28th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Biogen Idec (NASDAQ: BIIB) licensed its data analysis suite, MetaCore. Biogen Idec researchers can study their proprietary experimental data in the context of seven functional ontologies and unique merged metabolic/signaling networks. Importantly, MetaCore manually curated content now covers 12 organisms, and enables concurrent analysis of virtually any type of OMICs data including SNPs, MPSS files, microarray gene expression, proteomics, metabolomics and custom interactions. “Biogen Idec is such a great success story and we are pleased to help them in future achievements,” said Julie Bryant, GeneGo’s VP of Business Development. “The field of mammalian systems biology tools is mature by now, and they had multiple choices. We are glad they chose MetaCore.”
GENEGO INC LICENSES METACORE™ TECHNOLOGY TO PHILIPS St. Joseph, MI. July 31st 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Philips Research, one of the world’s largest industrial research institutes, has licensed its MetaCore™ technology. MetaCore™ is a very flexible pathway analysis platform that can be utilized with or without experimental data. It contains a lot of domain and disease knowledge that is easily accessible to general users which answers day to day questions of what is upstream or downstream of this gene or how are these metabolites linked via pathways, relevant papers to specific diseases or all papers on a compound binding with a specific ligand. “We are very pleased with Philips’ decision to license MetaCore™” said Julie Bryant, GeneGo’s VP of Business Development. “We have seen a surge of diagnostic companies, such as Almac Diagnostics becoming GeneGo customers over the last couple of years, and Philips is the latest addition. We welcome the expansion of the scope of systems biology applications beyond drug discovery.”
THE INSTITUTE FOR SYSTEMS BIOLOGY LICENSES METACORE™ FROM GENEGO St. Joseph, MI. July 24th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that The Institute for Systems Biology (ISB) has licensed its OMICs data analysis suite, MetaCore™ and 1-2-3 Workflow. All ISB researchers will have access to GeneGo pathway analysis and systems biology tools. MetaCore will be integrated with Cytoscape, an open source network visualization software supported by ISB. GeneGo and ISB also plan to collaborate on several research projects. ISB is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB’s systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time. “The manually curated content available from GeneGo is exceptional and will allow us to advance our projects,” said Dr Nat Goodman, a Senior Research Scientist at ISB. “We are initiating several research projects together that will hopefully result in publications.” “We are happy to welcome ISB as a customer and collaborator,” said Julie Bryant, GeneGo’s VP of Business Development. “ISB, led by Dr. Lee Hood, is the premium academic institution in our field, with outstanding research and vision. We are looking forward to working with them in systems biology of human diseases.”
EXPRESSION ANALYSIS ENTERS AGREEMENT WITH GENEGO TO PROVIDE FUNCTIONAL ANALYSIS SERVICES USING 1-2-3 WORKFLOW™ St. Joseph, MI. July 10th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Expression Analysis, Inc. will be providing functional analysis (pathways and networks) add-on services to their customers. Expression Analysis is the leading microarray services and solutions provider for clinical trials customers. GeneGo’s “1-2-3 Workflow™” automatically uploads and normalizes genomics data, compares multiple expression datasets to identify their common, similar and unique components, conducts enrichment analysis in multiple knowledge ontologies such as diseases, canonical pathways and functional processes and then calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report which will be supplied as an option with microarray assays delivered by Expression Analysis. “We are very pleased to be working with Expression Analysis as they offer excellent microarray services using standardized protocols for Affymetrix GeneChip® brand technology,” said Julie Bryant, GeneGo’s VP of Business Development.“1-2-3 Workflow™ is an ideal vehicle for value-add functional analysis for OMICs service organizations as it provides a very comprehensive report quickly and in an easy-to-understand Word format at a reasonable cost.” “Expression Analysis is committed to being a full-service genomics provider,” said Steve McPhail, CEO and President of Expression Analysis, Inc. “Our standard microarray service includes statistical analyses to identify differentially expressed genes. However, some investigators request help translating the gene list into functional relationships. The GeneGo service will provide this assistance using an established software product. We see it as a natural partnership for both companies and a definite value for our clients.” About Expression Analysis, Inc.: Expression Analysis, Inc. (http://www.expressionanalysis.com) is the industry's leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChip® microarrays, the company also provides complementary services using Illumina, Luminex and Applied Biosystems' TaqMan® technology.
DR. RICHARD BRENNAN JOINS GENEGO AS DIRECTOR OF TOXICOLOGY St. Joseph, MI. July 17th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, today announced the appointment of Dr. Richard Brennan as Director of Toxicology. Dr. Brennan is a Diplomate of the American Board of Toxicology and brings extensive experience in the pharmaceutical and biotechnology industry, with particular expertise in molecular toxicology and toxicogenomics. Dr. Brennan will lead the MetaTox Consortium, a joint industry and government effort focused on development of systems biology tools for prediction of human toxicity of new compounds. Dr. Brennans previous position was Director of Molecular and Investigative Toxicology at Iconix Biosciences, where he was a member of the team that delivered ToxFX, a toxicogenomics data management and analysis solution. Before that, Dr. Brennan was an Associate Director of Pharmacology and Cell Biology at Cornerstone Pharmaceuticals (Stony Brook, NY) and as Senior Scientist at OSI Pharmaceuticals (Farmingdale, NY). Dr. Brennan holds a Ph.D. in Chemistry from the University of Warwick, UK, and conducted post-doctoral research at the University of Manchester and at the Harvard School of Public Health before joining industry. “We welcome Richard to GeneGo team,” said Tatiana Nikolskaya, GeneGos founder and CSO. “At this point, the field of mammalian systems biology is getting diversified in specific application areas, such as common human diseases, drug safety and medicinal chemistry. Development of next generation products in these areas requires leaders with solid domain expertise, and Richard is both a Board certified expert toxicologist and a developer of systems analysis tools. The MetaTox project, partially supported by our NIEHS Phase II grant, will include toxicity ontologies, signature networks and functional descriptors models for different types of toxicity, as well as manual annotation of toxicity relevant pathways in human, rat, mouse and in vitro models.”
MONARCH LIFESCIENCES ENTERS AGREEMENT WITH GENEGO TO PROVIDE PATHWAY ANALYSIS SERVICES USING 1-2-3 WORKFLOW™ St. Joseph, MI. June 19th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Monarch LifeSciences will be offering pathway analysis add on services to their customers. Monarch is a contract research organization with expertise in protein biomarker discovery, development and validation. The 1-2-3 Workflow™ from GeneGo automatically uploads proteomics data, compares the datasets, identifies common, similar and unique components of the datasets, conducts enrichment analysis in multiple ontologies such as diseases, canonical pathways and functional processes; calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report. “We are very pleased to be working with Monarch as they offer excellent proteomics services, which is a growing OMICs field,” said Julie Bryant, GeneGo’s VP of Business Development. “Our goal in development of 1-2-3 Workflow™ was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences’ customers will be very happy with the analysis provided.” “Our goal is to provide our customers with reliable proteomics data that can easily integrate into their research programs,” said Lauri Caviston, Monarch LifeSciences’ VP of Business Development. “GeneGo provides an excellent tool for taking the data we generate to the next level.” About Monarch LifeSciences: Monarch LifeSciences provides services in protein biomarker discovery, development and validation for the pharmaceutical and biotech industries. Monarch’s biomarker discovery services include experimental design, proprietary sample preparation methods and quantification algorithms to ensure the generation of quality data. The LifeMarker™ Assay supports both pre-clinical and clinical applications of biomarkers and provides accurate high throughput analysis of proteins without the need for an antibody. For more information, please visit the company’s web site www.monarchlifesciences.com
CHENOMX AND GENEGO OFFER METABOLOMICS DATA INTEGRATION Manchester, United Kingdom, June 11, 2007 — Chenomx, Inc., a leading provider of software and compound libraries for NMR-based metabolomics, and GeneGo, Inc., a worldwide leader in data analysis solutions for systems biology and pathway analysis, are pleased to announce a partnership to provide metabolomics data integration between their software products. This partnership combines Chenomx’s powerful and easy-to-use metabolomics software, Chenomx NMR Suite, with GeneGo’s MetaCore and MetaDrug Discovery platform™, providing researchers with the ability to perform sophisticated pathway analysis and visualization. “Chenomx’s partnership with GeneGo offers several significant advantages to our shared customers,” explains Jack Newton, Director of Product Development for Chenomx. “First, our customers will now be able to combine Chenomx NMR Suite’s powerful metabolite identification and quantification capabilities with GeneGo’s pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology. This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data.” “We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data,” said Julie Bryant VP of business development. “Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software”. About Chenomx, Inc. Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities’ research efforts. Chenomx’s flagship product, Chenomx NMR Suite, provides a rich set of tools for identifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions is available at www.chenomx.com.
GENEGO LICENSES MEDCHEM DATABASE FROM GVK BIOSCIENCES Hyderabad - India & St Joseph, MI, USA, June 2, 2007 — GVK Biosciences (GVK BIO) announced that it has licensed its Medicinal Chemistry Database (MCD) to GeneGo, a leading provider of databases, software and services in systems biology. MCD has over 800,000 small molecule inhibitors and has associated 3 million quantitative SAR information manually extracted from over 42,000 medicinal chemistry journal articles. GeneGo will integrate this data into MetaCore™ and MetaDrug™, designed for biology and chemistry aspects of drug discovery process, respectively G V Sanjay Reddy, Chief Executive Officer, GVK BIO: “We are excited to be working with Genego, the leading pathway analysis and systems biology company in this space. GeneGo has definitely has been an innovator in this field and we are pleased to be associated with them. Their unique chemistry offering fits well with GVK BIO database collections.”. Julie Bryant, Vice President Business Development, GeneGo commented: “We are very pleased to work with GVK BIO. GeneGo, like our end users, drug companies, have to make “build versus buy” decisions, but it is difficult to find content that fits our high quality criteria and adds value to the databases we have already assembled. This is the first time we have accepted any third party content”. Informatics at GVK BIO The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies. About GVK BIO GVK Biosciences is one of Indias premier Contract Research Organizations, providing an integrated platform of research services across the Pharma R&D value chain to a growing number of global Pharma and Biotech companies. The company combines science, innovation and resources to help clients address their Drug Discovery and Development challenges. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.
GENEGO AWARDED PHASE II TOXICOGENOMICS GRANT BY NIEHS St. Joseph, MI. May 15th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that they have received a $750,000 Phase II SBIR grant from National Institute of Environmental Health Sciences (NIEHS) for the development of functional descriptors for gene expression response to drugs and toxins as part of their MetaTox™ product line. “Toxicogenomics is a mature OMICs field, with a huge amount of drug response data accumulated in industry and the public domain”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “However, one third of compounds are still withdrawn from clinical trials due to human toxicity unseen in pre-clinical toxicogenomics profiling. We see the problem not in the approach itself, but in data interpretation techniques, heavily focused on statistics-derived gene signatures. In this grant, we propose to develop a new concept of functional descriptors and network models for toxicogenomics data analysis, and we are happy that NIEHS share this vision”.
BOEHRINGER INGELHEIM EXPANDS GENEGO LICENSES TO GLOBAL AGREEMENT St. Joseph, MI. April 10th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments. The agreement covers a suite of software tools and databases for functional data analysis MetaCore™, which is used for biomarker discovery, target identification and validation. MetaCore™ features a unique set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry. “We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore™ seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology” said Julie Bryant, GeneGo’s VP of Business Development. “We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore™ that they are not getting from other tools.”
GENEGO WINS FROST & SULLIVAN AWARD FOR BIOINFORMATICS OURSOURCING AND COMPETITIVE STRATEGY YIELDING SIGNIFICANT COMPETITIVE MARKET GAINS St. Joseph, MI. March 13th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that they have been awarded a 2006 competitive strategy and bioinformatics outsourcing leadership award from Frost & Sullivan, competing with 150 other companies in Life sciences. Frost & Sullivan cited that GeneGo’s innovative competitive strategy had yielded significant market gains and their analysts expect such innovations will produce lasting, precedent setting trends. This information was gathered by interviews with the experts in the field, end users and the companies themselves. Frost & Sullivan also state that GeneGo is ahead in terms of innovativeness and product quality and has the unique ability to cover the whole spectrum of systems biology that other companies miss. “The reason why GeneGo Inc.’s competitive approach in the Bioinformatics market has been considered successful is because this makes the company appear attractive in terms of profitability, sustained commercial viability and technical competence”, says Frost & Sullivan Analyst Sumitha Kannan. “The scientific community perceives the company as having a clear vision of its needs and a strategic focus on potential future growth areas.” “We are honored to receive this award and understand its importance in this competitive field. This award is yet another validation of the high standards that GeneGo sets in the systems biology and pharmacology field” said Julie Bryant, GeneGo’s VP of Business development. “We would also like to acknowledge help and support from our customers and partners whose feedback is really important in our product development.” To download the white paper please click here.
GENEGO’S METADRUG™ WON THE BEST IN SHOW NEW PRODUCT AWARD AT THE 2007 MOLECULAR MEDICINE MEETING St. Joseph, MI. March 7th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that its systems pharmacology product MetaDrug 2.0™ won the “Best in Show” product award at the CHI’s Molecular Medicine Marketplace (MMM) conference held in San Francisco last week. MetaDrug™ was chosen a winner among six other systems biology products by conference attendee votes. MetaDrug™ helps to predict indications, off target effects and human toxicity for novel small molecules compounds using systems level chemoinformatics tools and manually annotated knowledge base of compound-target interactions, diseases, toxic categories, drug and endogenous metabolic pathways and signaling interactions. “We are very pleased with winning this award”, said Julie Bryant, GeneGo’s VP of Business development. “MMM is the most important trade show in our field and is attended by the top experts in systems biology, translational medicine and medicinal chemistry, whose opinion matters a great deal for us. This year, we took a considerable risk with MetaDrug™, our second product, as it competed with the latest versions of flagship suites launched by our competitors at MMM. We are glad this risk paid off”. “MetaDrug™ is a unique platform”, said Tatiana Nikolskaya, GeneGo’s CSO and President. “There are probably a hundred commercial and open source products for pathway and network analysis of biological data but virtually nothing for chemistry. Prediction of biological effects for small molecules is a tough problem. Structure-centered chemoinformatics tools do not help explain systems level effects like disease indications; and simple assembly of ligand-receptor interactions databases are not sufficient either. We spent almost three years developing patent-pending MetaDrug™ technology and we are very glad it is appreciated by the market. We are also grateful to NIH which supported MetaDrug™ with SBIR grants”
GENEGO LAUNCHES “PAY AS YOU GO” 1-2-3 WORKFLOW™ AT THE MOLECULAR MEDICINE TRI CONFERENCE St. Joseph, MI. February 27th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today the release of a new product, 1-2-3 Workflow™, accessible via a “pay-as-you-go” model. This easy to use workflow provides casual users with an automated comprehensive functional analysis of multiple gene lists in just two clicks. All the processing is done in the background and the customers receive a report in a formatted Word file which can be shared with colleagues. “We are very pleased to release this new “pay-as-you-go” product,” said Julie Bryant, GeneGo’s VP of Business Development. “We developed it based on many requests from our “Google-generation” customers who want the basic analysis done “within 30 minutes with one click”. The trick was to combine the “ease of use” functionality with high quality analysis GeneGo is known for and sophistication of algorithms necessary for analysis of genome-wide datasets accessing the highest quality content in MetaCore™” “1-2-3 Workflow™ is not about stripping-down functions of our larger product, MetaCore™&rdqou;, says Tatiana Nikolskaya, GeneGo’s President and CSO.“You can consider it as a “condensed wisdom” of our data mining projects run in house in several disease areas and toxicity for several years. We wrapped this knowledge and “know how” up into a workflow with several knowledge ontologies for enrichment analysis, the most advanced network building algorithms we have and our experience in finding the most relevant biomarkers and targets”.
ST. JUDE CHILDREN’S RESEARCH HOSPITAL LICENSES METACORE FROM GENEGO St. Joseph, Michigan, January 30th, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that St. Jude Children’s Research Hospital has licensed its data mining suite MetaCore. The latest version MetaCore 4.2 includes a novel GeneGo ontology of cellular process networks, which goes a step beyond GO ontology which is also available in MetaCore. It contains additional functional processes and more genes have been networked using GeneGo proprietary network algorithms. MetaCore has an in depth knowledge base for pediatric cancer and the unique ability to concurrently visualize gene expression and proteomics data. MetaCore also covers many species including human, mouse, rat, chicken, dog, worm, yeast and chimpanzee. MetaCore spans research, discovery and clinical trials.
GENEGO AND SPOTFIRE PARTNER TO DELIVER FASTER GENOMICS AND CHEMISTRY ANALYSIS GeneGo’s MetaCore and Spotfire DecisionSite Fully Integrated to Improve Pharmaceutical Discovery Workflow St. Joseph, Michigan, January 23rd, 2007 — GeneGo, Inc., a leading provider of software and databases for systems biology and Spotfire, the Information Insight CompanySM, today announced that the companies’ flagship products are fully integrated. The integrated products allow users to analyze genomics data, including gene expression and proteomics, more quickly and accurately in Spotfire DecisionSite, and launch MetaCore to perform pathway and network analysis. DecisionSite users can also automatically upload chemical compounds into MetaCore and MetaDrug in order to study their biological effects, including mode of action and potential toxicity. The analyzed data can be sent back to DecisionSite, allowing the user to search for additional experiments run in house. “The integration between DecisionSite and MetaCore and MetaDrug provides our mutual customers with a more powerful environment, improving workflow and accelerating discovery from their experimentation and content,” said Christian Marcazzo, Senior Director of Life Science Analytics for Spotfire. “This integration is a brilliant demonstration of the flexibility of the DecisionSite platform to evolve with the changing needs of our pharmaceutical industry customers.” “We received numerous requests from our mutual customers for seamless integration with Spotfire. This integration is unique as both GeneGo’s and Spotfire’s products enable concurrent analysis and display of both biological and chemistry data” said Julie Bryant, Vice President of Business Development at GeneGo. “GeneGo has an open partnering philosophy and we always look forward for expansion of our product integration space. We are very pleased with the current project with Spotfire, the dominant player in the data analysis market.” About Spotfire Spotfire, the Information Insight CompanySM, is a leading provider of enterprise analytics software that helps professionals quickly discover new and actionable insights in information. For thousands of business professionals faced with day-to-day decisions, Spotfire offers a visual and interactive analytics experience that helps them make decisions with speed and confidence. Distinguished by its ease of use and analytic power, Spotfire software rapidly reveals unseen threats and illuminates new opportunities, creating significant economic value. Spotfire’s customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit www.spotfire.com. Spotfire, DecisionSite and Spotfire DXP are trademarks or registered trademarks of Spotfire, Inc., except in the European Community where Spotfire and the products listed are trademarks of Spotfire AB. Other company or product names may be the trademarks of their respective owners.
|
